{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T01:28:08Z","timestamp":1780968488496,"version":"3.54.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.clml.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T15:02:26Z","timestamp":1302879746000},"page":"228-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide\/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens"],"prefix":"10.1016","volume":"11","author":[{"given":"Maurizio","family":"Zangari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.03.006_bib1","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib2","doi-asserted-by":"crossref","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2011.03.006_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2011.03.006_bib4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","article-title":"Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis","volume":"46","author":"Uaprasert","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2011.03.006_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-2003-40965","article-title":"The blood coagulation mechanism in multiple myeloma","volume":"29","author":"Zangari","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2011.03.006_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737140.7.3.307","article-title":"Thrombosis in multiple myeloma","volume":"7","author":"Zangari","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2011.03.006_bib7","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib8","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3816\/CLM.2007.n.027","article-title":"Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders","volume":"7","author":"Auwerda","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2011.03.006_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2011.03.006_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.thromres.2007.05.016","article-title":"In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide","volume":"121","author":"Petropoulou","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2011.03.006_bib12","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"van Marion","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.03.006_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.clml.2011.03.006_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.03.006_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1160\/TH06-02-0080","article-title":"Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations","volume":"95","author":"Hussein","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2011.03.006_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.006_bib17","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","article-title":"Thrombotic events in patients with cancer receiving antiangiogenesis agents","volume":"27","author":"Zangari","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH06-09-0494","article-title":"Thalidomide and thrombosis","volume":"97","author":"El Accaoui","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2011.03.006_bib19","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1001\/jama.296.21.2558-c","article-title":"Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer","volume":"296","author":"Bennett","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2011.03.006_bib20","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.006_bib21","doi-asserted-by":"crossref","first-page":"423s","DOI":"10.1200\/jco.2006.24.18_suppl.7506","article-title":"Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin","volume":"24","author":"Niesvizky","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2009.23.0169","article-title":"Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone","volume":"28","author":"Zangari","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2011.03.006_bib24","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.6004\/jnccn.2010.0112","article-title":"Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia","volume":"8","author":"Niesvizky","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2011.03.006_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-0925-1","article-title":"Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma","volume":"89","author":"Palumbo","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2011.03.006_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00277-008-0561-1","article-title":"Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone","volume":"88","author":"Klein","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2011.03.006_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/MBC.0b013e32832b27e6","article-title":"Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism","volume":"20","author":"Talamo","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.clml.2011.03.006_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1600-0609.2010.01434.x","article-title":"Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin","volume":"84","author":"Cini","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.03.006_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00277-004-0891-6","article-title":"Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone","volume":"83","author":"Corso","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2011.03.006_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1600-0609.2006.00733.x","article-title":"Thrombomodulin levels are not modified during thalidomide treatment","volume":"77","author":"Zappasodi","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.03.006_bib31","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","article-title":"Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping","volume":"112","author":"Johnson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1538-7933.2003.00573.x","article-title":"Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology","volume":"2","author":"Kaushal","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2011.03.006_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1160\/TH07-08-0495","article-title":"Cathepsin G, a leukocyte protease, activates coagulation factor VIII","volume":"99","author":"Gale","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2011.03.006_bib35","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2011.03.006_bib36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.006_bib37","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S1557-9190(11)70505-4","article-title":"Erythropoiesis-stimulating agents: no impact on long-term outcome in MM patients in the VISTA trial","volume":"9","author":"Richardson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2011.03.006_bib38","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.006_bib39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.2008.07321.x","article-title":"Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma","volume":"143","author":"Lonial","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.03.006_bib40","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.2006.06.1853","article-title":"Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer","volume":"24","author":"Fanucchi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib41","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1200\/JCO.2009.22.7066","article-title":"Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402","volume":"27","author":"Lilenbaum","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib42","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/JTO.0b013e3181aba89f","article-title":"A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer","volume":"4","author":"Lynch","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.lungcan.2009.07.011","article-title":"A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer","volume":"68","author":"Scagliotti","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clml.2011.03.006_bib44","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/sj.bjc.6604347","article-title":"Bortezomib\/docetaxel combination therapy in patients with anthracycline-pretreated advanced\/metastatic breast cancer: a phase I\/II dose-escalation study","volume":"98","author":"Awada","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2011.03.006_bib45","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-06-2046","article-title":"Phase I\/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer","volume":"13","author":"Dreicer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.03.006_bib46","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1200\/JCO.2007.14.0152","article-title":"Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study","volume":"26","author":"Kozuch","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib47","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1158\/1078-0432.CCR-05-0081","article-title":"A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer","volume":"11","author":"Mackay","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.03.006_bib48","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.12522","article-title":"Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma","volume":"93","author":"Zangari","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.03.006_bib49","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thromres.2007.06.013","article-title":"Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro","volume":"121","author":"Avcu","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2011.03.006_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1160\/TH03-11-0707","article-title":"Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats","volume":"92","author":"Ostrowska","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2011.03.006_bib51","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib52","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.03.006_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V114.22.131.131","article-title":"Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa trial)","volume":"114","author":"Einsele","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib54","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib55","doi-asserted-by":"crossref","first-page":"60a","DOI":"10.1182\/blood.V114.22.132.132","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: updated results of phase I\/II MMRC trial","volume":"114","author":"Jakubowiak","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib56","doi-asserted-by":"crossref","first-page":"605s","DOI":"10.1200\/jco.2010.28.15_suppl.8131","article-title":"A comparison of lenalidomide\/dexamethasone (RD) versus cyclophosphamide\/lenalidomide\/dexamethasone (CRD) versus cyclophosphamide\/bortezomib\/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM)","volume":"28","author":"Khan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib57","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib58","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib59","doi-asserted-by":"crossref","first-page":"576s","DOI":"10.1200\/jco.2010.28.15_suppl.8014","article-title":"Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study","volume":"28","author":"Moreau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib60","first-page":"144","article-title":"Phase 3b UPFRONT study: Interim results from a community-based prospective randomized trial evaluating three bortezomib-based regimens in elderly, newly diagnosed multiple myeloma patients","volume":"95","author":"Niesvizky","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.03.006_bib61","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib62","doi-asserted-by":"crossref","first-page":"59a","DOI":"10.1182\/blood.V114.22.130.130","article-title":"Thalidomide \/ dexamethasone (TD) vs. bortezomib (Velcade) \/ thalidomide \/ dexamethasone (VTD) vs. VBMCP\/VBAD\/Velcade as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA\/GEM trial","volume":"114","author":"Rosi\u00f1ol","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib63","first-page":"243a","article-title":"First analysis of HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)","volume":"114","author":"Sonneveld","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib64","doi-asserted-by":"crossref","first-page":"255a","DOI":"10.1182\/blood.V114.22.616.616","article-title":"A phase II trial comparison of once versus twice weekly bortezomib in CYBORD chemotherapy for newly diagnosed myeloma: identical high response rates and less toxicity","volume":"114","author":"Reeder","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib65","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.03.006_bib66","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Gay","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib67","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood.V112.11.91.91","article-title":"Phase II trial of lenalidomide (Revlimid\u2122) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma","volume":"112","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib69","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib70","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib71","doi-asserted-by":"crossref","first-page":"22a","DOI":"10.1182\/blood.V108.11.57.57","article-title":"Dexamethasone + thalidomide (Dex\/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): A randomized trial","volume":"108","author":"Macro","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib72","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.03.006_bib73","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2013Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib74","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib75","doi-asserted-by":"crossref","first-page":"253a","DOI":"10.1182\/blood.V114.22.613.613","article-title":"A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma","volume":"114","author":"Palumbo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib78","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib79","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib80","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib81","doi-asserted-by":"crossref","first-page":"576s","DOI":"10.1200\/jco.2010.28.15_suppl.8015","article-title":"A phase III trial of melphalan\/prednisone\/lenalidomide (MPR) versus melphalan (200 mg\/m2) and autologous transplantation (MEL200) in newly diagnosed myeloma patients","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.006_bib82","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1182\/blood.V104.11.4914.4914","article-title":"Protective effect of VELCADE\u00ae on thalidomide-associated deep vein thrombosis (DVT)","volume":"104","author":"Zangari","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib83","doi-asserted-by":"crossref","first-page":"203a","DOI":"10.1182\/blood.V114.22.492.492","article-title":"A phase III study of enoxaparin vs aspirin vs low-dose warfarin as thromboprophylaxis for newly diagnosed myeloma patients treated with thalidomide based-regimens","volume":"114","author":"Palumbo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib84","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bcp.2009.12.021","article-title":"Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action","volume":"79","author":"Miller","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clml.2011.03.006_bib85","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MOH.0b013e328302c7f4","article-title":"NF-kappaB in the pathogenesis and treatment of multiple myeloma","volume":"15","author":"Li","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2011.03.006_bib86","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/jpet.103.054346","article-title":"Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells","volume":"307","author":"Hamaguchi","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2011.03.006_bib87","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1182\/blood-2004-03-0928","article-title":"Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B","volume":"105","author":"Sohn","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.006_bib88","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1074\/jbc.M806010200","article-title":"NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis","volume":"284","author":"Li","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.03.006_bib89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1067\/mtc.2003.99","article-title":"Nuclear factor kappaB mediates a procoagulant response in monocytes during extracorporeal circulation","volume":"125","author":"Morgan","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clml.2011.03.006_bib90","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1161\/ATVBAHA.109.191957","article-title":"Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Kruppel-like transcription factors","volume":"29","author":"Hiroi","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clml.2011.03.006_bib91","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1160\/TH05-07-0477","article-title":"Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator","volume":"95","author":"Zhang","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2011.03.006_bib92","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/STROKEAHA.109.577288","article-title":"Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia","volume":"41","author":"Zhang","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.clml.2011.03.006_bib93","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/dna.2006.25.340","article-title":"1 is degraded in differentiation of erythrocytes through a proteasome-dependent pathway","volume":"25","author":"Konishi","year":"2006","journal-title":"DNA Cell Biol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:14Z","timestamp":1761870074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S2152265011000073"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide\/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}